These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26039995)

  • 1. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition.
    Su TH; Shiau CW; Jao P; Liu CH; Liu CJ; Tai WT; Jeng YM; Yang HC; Tseng TC; Huang HP; Cheng HR; Chen PJ; Chen KF; Kao JH; Chen DS
    Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7243-8. PubMed ID: 26039995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis.
    Su TH; Shiau CW; Jao P; Yang NJ; Tai WT; Liu CJ; Tseng TC; Yang HC; Liu CH; Huang KW; Hu TC; Huang YJ; Wu YM; Chen LJ; Chen PJ; Chen DS; Chen KF; Kao JH
    Sci Rep; 2017 May; 7(1):1728. PubMed ID: 28496142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
    J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
    Deng YR; Ma HD; Tsuneyama K; Yang W; Wang YH; Lu FT; Liu CH; Liu P; He XS; Diehl AM; Gershwin ME; Lian ZX
    J Autoimmun; 2013 Oct; 46():25-34. PubMed ID: 23948302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
    J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
    Liu CY; Tseng LM; Su JC; Chang KC; Chu PY; Tai WT; Shiau CW; Chen KF
    Breast Cancer Res; 2013; 15(4):R63. PubMed ID: 23938089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
    Tai WT; Shiau CW; Chen PJ; Chu PY; Huang HP; Liu CY; Huang JW; Chen KF
    Hepatology; 2014 Jan; 59(1):190-201. PubMed ID: 23908138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis.
    Wang Z; Li J; Xiao W; Long J; Zhang H
    Lab Invest; 2018 Dec; 98(12):1600-1613. PubMed ID: 30206312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
    Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
    Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
    Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
    Tai WT; Shiau CW; Chen HL; Liu CY; Lin CS; Cheng AL; Chen PJ; Chen KF
    Cell Death Dis; 2013 Feb; 4(2):e485. PubMed ID: 23392173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.
    Hong F; Chou H; Fiel MI; Friedman SL
    Dig Dis Sci; 2013 Jan; 58(1):257-64. PubMed ID: 22918681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis.
    Xiang DM; Sun W; Ning BF; Zhou TF; Li XF; Zhong W; Cheng Z; Xia MY; Wang X; Deng X; Wang W; Li HY; Cui XL; Li SC; Wu B; Xie WF; Wang HY; Ding J
    Gut; 2018 Sep; 67(9):1704-1715. PubMed ID: 28754776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells.
    Martí-Rodrigo A; Alegre F; Moragrega ÁB; García-García F; Martí-Rodrigo P; Fernández-Iglesias A; Gracia-Sancho J; Apostolova N; Esplugues JV; Blas-García A
    Gut; 2020 May; 69(5):920-932. PubMed ID: 31530714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
    Chen Y; Huang Y; Reiberger T; Duyverman AM; Huang P; Samuel R; Hiddingh L; Roberge S; Koppel C; Lauwers GY; Zhu AX; Jain RK; Duda DG
    Hepatology; 2014 Apr; 59(4):1435-47. PubMed ID: 24242874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
    Tai WT; Shiau CW; Li YS; Chen YL; Chu PY; Huang JW; Hsu CY; Hsu YC; Chen PJ; Chen KF
    Mol Cancer Ther; 2014 Jan; 13(1):27-36. PubMed ID: 24275147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
    Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.